LONDON, July 23 (Reuters) - The European Union's drug watchdog cast further doubt on recent studies suggesting a possible cancer risk with Sanofi-Aventis's widely-used Lantus diabetes drug. The ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. U.S. regulators took action Wednesday that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results